Introduction
Approximately 50% of the population experience symptoms of insomnia on a
regular basis. However, only a fraction of patients are diagnosed, with even
fewer receiving prescribed pharmacological therapy. Currently Sanofi's Ambien (zolpidem)
is the market leader across the seven major markets, with revenues of $1.7
billion in 2003.
Scope of this report
- Overview of the epidemiology of insomnia in order to assess the untapped
patient potential offered by this disorder
- Analysis of why the US insomnia market has flourished, and of how similar
success can be achieved in Europe in the future
- Evaluation of the current market leaders and primary contenders for
entrance in to the market
- Assessment of product positioning and life-cycle management strategies of
branded and pipeline manufacturers
Research and analysis highlights
- Datamonitor estimates that approximately 67 million insomnia patients will
receive prescribed drug therapy in 2004 across the seven major markets,
although the potential patient population is considerably higher at 238
million across the seven major markets.
- Ambien is currently the market-leading insomnia drug, with a 94% share of
the branded insomnia market. However, the drug will face increasing
competition with the launch of generic zolpidem and numerous novel drugs.
- Sepracor's Estorra and Neurocrine/Pfizer's indiplon are expected to reach
market during 2005, and will drive the growth of the insomnia market, both
reaching blockbuster status within the forecast period.
Key reasons to read this report
- Analyze the commercial viability of the insomnia market, based on
estimated patient numbers, historical and forecast sales data
- Develop an understanding of key unmet needs of the insomnia market, market
entry and consolidation strategies a current and future players
- Identify and assess novel R&D compounds in the insomnia pipeline
View Cart
